Characterization of the Platelet Phenotype Caused by a Germline RUNX1 Variant in a CRISPR/Cas9-Generated Murine Model

Ana Marín-Quílez1, Ignacio García-Tuñón1, Cristina Fernández-Infante1

  • 1Cancer Research Center - CSIC, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain.

Thrombosis and Haemostasis
|February 24, 2021
PubMed

Insights

RUNX1-related disorder (RUNX1-RD) is caused by variants in the RUNX1 gene. A new mouse model shows the RUNX1 p.Leu56Ser variant impairs platelet function, mimicking human disease phenotypes.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • RUNX1-related disorder (RUNX1-RD) results from germline variants in the RUNX1 gene, presenting a diagnostic challenge due to its heterogeneous nature and lack of a specific phenotype.
  • International guidelines exist for variant classification, but determining pathogenicity and understanding molecular pathogenesis for RUNX1-RD requires further investigation.

Purpose of the Study:

  • To develop and characterize a knock-in murine model for the RUNX1 p.Leu43Ser variant (human p.Leu56Ser) to investigate its pathogenic effects on platelet function.
  • To elucidate the molecular mechanisms underlying platelet dysfunction in RUNX1-RD.

Main Methods:

  • CRISPR/Cas9 gene editing was used to create a knock-in mouse model with the RUNX1 p.Leu43Ser variant.
  • Generated three genotypes: RUNX1 wild-type/wild-type (WT/WT), RUNX1 WT/L43S, and RUNX1 L43S/L43S.
  • Assessed platelet phenotype using flow cytometry, confocal microscopy, tail-bleeding time, agonist-induced spreading, granule secretion, integrin activation, and PKC phosphorylation.

Main Results:

  • Mice with the RUNX1 L43S variant (homozygous and heterozygous) exhibited prolonged tail-bleeding times, indicating impaired hemostasis.
  • Homozygous mice showed mild thrombocytopenia. Both variant genotypes displayed impaired agonist-induced platelet spreading and alpha-granule release.
  • Deficits in integrin αIIbβ3 activation, fibrinogen binding, and aggregation were observed, alongside reduced PKC phosphorylation, suggesting impaired PKC signaling.

Conclusions:

  • The RUNX1 p.Leu56Ser variant has deleterious effects in mice, impairing key platelet functions such as integrin activation, aggregation, and granule secretion.
  • This murine model successfully mimics clinical phenotypes associated with RUNX1 variants, providing a valuable tool for studying RUNX1-RD pathogenesis.
  • The findings highlight the role of the PKC signaling pathway in RUNX1-mediated platelet dysfunction.

Related Concept Videos